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Sugars, primarily glucose and fructose, are the main energy source of cells. Because of their hydrophilic nature, cells use a number
of transporter proteins to introduce sugars through their plasma membrane. Cancer cells are well known to display an enhanced
sugar uptake and consumption. In fact, sugar transporters are deregulated in cancer cells so they incorporate higher amounts of
sugar than normal cells. In this paper, we compile the most significant data available about biochemical and biological properties
of sugar transporters in normal tissues and we review the available information about sugar carrier expression in diﬀerent types of
cancer. Moreover, we describe the possible pharmacological interactions between drugs currently used in anticancer therapy and
the expression or function of facilitative sugar transporters. Finally, we also go into the insights about the future design of drugs
targeted against sugar utilization in cancer cells.
1. Introduction
In animal cells, sugars are the major source of metabolic
energy. However, as the plasma membrane is impermeable
to polar molecules, membrane-associated carrier proteins
are necessary for the introduction of sugars in cells. There
are two described families of transporters: GLUT [solute
carrier family 2 (facilitated glucose transporter), gene name
SLC2A] and SGLT [solute carrier family 5 (sodium/glucose
cotransporter); gene name: SLC5A]. GLUT transporters use
existing gradients in sugar concentration, between external
and internal sides of plasma membrane, to facilitate its
translocation. Conversely, SGLT proteins move sugars inside
of cells against gradient concentration, with the consequent
energy cost. There are distinct GLUT genes encoding distinct
GLUT transporters, which share an important sequence
homology, although they display diﬀerent aﬃnity for sugars
and present a marked tissue-specific expression pattern.
Among all sugars, glucose is the most used by cells. Glucose
uptake is the rate-limiting step in its use, underlining the
importance of GLUT transporters in metabolism.
Glycolysis is the catabolic pathway by which glucose
undergoes the first transformation to obtain energy. In
normal cells, after glycolysis, glucose is further metabolized
through tricarboxilic acid cycle and oxidative phosphory-
lation in mitochondria. However, cancer cells display an
increased consumption of glucose [1] which is metabo-
lized primarily through the fermentative pathway with the
consequent lactic acid production [1, 2]. Probably, the
use of fermentative catabolism by cancer cells is due to a
mitochondrial malfunction [1, 2]. As result, the oxidative
catabolism, which is more eﬃcient in energy production, is
impaired in cancer cells. The fermentation pathway carried
out by cancer cells implies the consumption of more sugar to
fulfill their energy requirements. Indeed, distinct studies have
shown the glucose transporter induction during malignant
transformation [3]. In cancer cells, it has been also proposed
an enhanced activity of glycolytic enzymes, especially the
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activity of the enzyme hexokinase, which phosphorylates
glucose to avoid its exit from the cell and to maintain its
transmembrane gradient.
In this paper, we reviewed data available about the nor-
mal behavior of sugar transporters, as well as their expression
in malignant lesions and their possible pharmacological
modulation by new anticancer drugs.
2. Expression and Roles of Sugar Transporters
in Normal Tissues
2.1. Sugar Transporters. Sugars are primarily obtained from
the diet after the hydrolysis of disaccharides and polysac-
charides, although it is also possible that their synthesis
can happen in organs such as liver. The dietary sugars
are captured by enterocytes that coat the lumen of small
intestine. In addition, both dietary and synthesized sugars
must be transferred to blood for their transport along
organism. This sugar transport is performed through sugar
transporter proteins, located at plasma membrane of cells.
The location of sugar transporters is intracellularly regulated
by polarity, especially in enterocytes, where each side (apical-
luminal or basolateral) of cell displays specific transporters
with diﬀerent features. In addition, sugar transporters show
also a tissue-specific expression, and this expression reflects
the physiological characteristics of each tissue in relation
to sugar transporter features. There are two types of sugar
transporters depending on their use of energy for sugar
transport: Na+-dependent sugar cotransporters (SGLT),
which require energy for sugar transport, and facilitative
Na+-independent sugar transporters (GLUT), which utilize
sugar concentration gradient tomove it throughmembranes.
2.2. Sodium-Dependent Sugar Transporters. The family of
SGLT transporters comprises the sodium-glucose sym-
porters SGLT1 and SGLT2, the glucose sensor SGLT3, the
multivitamin transporters SGLT4 and SGLT6, as well as the
thyroid iodide transporter SGLT5. Their predicted secondary
structures contain fourteen transmembrane helices with
their N-terminus and C-terminus regions orientated to the
extracellular face. SGLT1 and SGLT2 are carrier proteins that
move glucose and also galactose with much lower aﬃnity.
They transport these sugars across the plasma membrane
against gradient concentration, with the consequent energy
expenditure. SGLT1 and SGLT2 proteins are able to exchange
sugars with sodium ions through the membrane to carry
out this transport. The sodium electrochemical gradient
necessary to this transport is generated by the Na+-K+ pump,
which uses ATP to transport sodium against its gradient con-
centration. SGLT1 expression is found essentially restricted
at the apical membranes of enterocytes from small intestine
and cells from renal proximal tubules (S3 cells). SGLT2
is expressed predominantly on apical membranes of cells
from renal convoluted proximal tubules (S1 and S2 cells).
SGLT2 shows low aﬃnity and high capacity to transport
glucose while SGLT1 displays high aﬃnity and low capacity
of transport. Thus, in kidney, SGLT2 is responsible for the
recovery of the bulk of plasma glucose from glomerular
filtrate, while SGLT1 is responsible for recuperation of the
remaining glucose, avoiding its loss in urine [4, 5].
2.3. Facilitative Sugar Transporters. Facilitative sugar trans-
porters, GLUTs, contrary to SGLTs, move sugars (including
glucose, fructose, and other hexoses) across cell membrane,
without energy consumption and in favor of gradient
concentration. To date, it has been identified fourteen GLUTs
[4–6], grouped in three classes, depending on their structural
and sequence similarity. However, there is a high degree of
homology between these GLUT transporters, which share
common features: they have twelve transmembrane domains
with intracellular carboxyl- and amino-ends and display
conserved glycine and tryptophan residues, which may
be essential for their function [5]. The most remarkable
diﬀerence between class I and II, and class III members is the
position of a predicted long extracellular loop. This loop, in
members of class I and II, is located between transmembrane
domains 1 and 2, and contains a glycosylation site which
appears to modulate their capacity of transport. The class
III members contain this extracellular loop with their
glycosylation sites between transmembrane domains 9 and
10 [5–7]. The model that explains the movement of sugar by
GLUTs is based on the adoption of two exclusive alternative
conformations of transporters: in one conformation GLUTs
expose a binding site for sugar to extracellular side of
plasmamembrane, while in the second conformation GLUTs
expose this binding site to the intracellular side of plasma
membrane. The binding of glucose (or other compatible
sugars) to one of these two sites triggers a conformational
change of GLUT transporters to one or other conformation.
In this process, sugars are moved across plasmamembrane in
any of the two directions [6]. However, despite similarities,
GLUTs display diﬀerent capabilities to transport distinct
sugars and they also present diﬀerent regulation and diﬀerent
distribution among tissues. In particular, GLUT tissue-
specific expression (Table 1) may play important roles in
the regulation of glucose uptake and its metabolism, under
distinct nutritional and hormonal conditions [4, 5].
2.4. Class I Facilitative Sugar Transporters. Class I of facilita-
tive sugar transporters is formed by GLUT1-4 and GLUT14
[4]. GLUT1 was the first facilitative sugar transporter dis-
covered, and is able to transport primarily glucose, although
it can also move galactose, mannose, and glucosamine with
distinct eﬃciencies. GLUT1 is responsible for basal glucose
uptake required to maintain respiration in cells, and its
expression is usually correlated with the rate of glucose
metabolism and respiration. Therefore, although GLUT1 is
expressed along virtually all tissues in normal conditions,
the highest levels are found in erythrocytes (due to this it
is also called erythrocyte-type glucose transporter) and in
endothelial cells from blood-tissue barriers, particularly in
blood-brain barrier [6]. Nevertheless, recent findings have
shown that high GLUT1 expression is not a ubiquitous fact
among erythrocytes from all species [8]. Thus, high GLUT1
expression in erythrocytes is restricted to species unable
to synthesize vitamin C from glucose, such as in species
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Table 1: Substrate specificity and tissue expression of sugar transporters.
Transporter
Substrates Tissues
Glucose Fructose Intestine Kidney Blood Liver Brain Pancreas Testis Muscle Heart Fat
SGLT1 X X X
SGLT2 X X
GLUT1 X X X
GLUT2 X X X X X
GLUT3 X X X
GLUT4 X X X X
GLUT5 X X X X
GLUT6 X X X
GLUT7 X X X X X
GLUT8 X X X X
GLUT9 X X X
GLUT10 X X X X X X X
GLUT11 X X X X X X
GLUT12 X X X X
GLUT14 X X
of primates (including humans), guinea pigs, or fruit bats.
Probably, the high expression of GLUT1 in erythrocytes
from these species is related to GLUT1-mediated transport
of vitamin C during erythroid diﬀerentiation [8]. Finally,
GLUT1 expression is repressed by p53, an important tumor
suppressor in cancer [9]. The alteration in p53 expression
may explain GLUT1 overexpression observed in many cancer
types, as well as their enhanced glucose metabolism and their
higher energy consumption.
GLUT2 is primarily a glucose transporter (although it
displays the highest aﬃnity for glucosamine) that shows
low aﬃnity for fructose, galactose, and mannose. GLUT2 is
expressed in basolateral membrane of intestinal absorptive
epithelium where it is responsible for the transport of
fructose and glucose (introduced in enterocytes through
SGLT1 which generates a favorable concentration gradient)
to blood. In addition, GLUT2 is also expressed in basolateral
surface of kidney absorptive cells, where it plays a similar
function that in intestine, absorbing glucose from filtrate to
blood. In liver, GLUT2 is located in the sinusoidal membrane
where it is involved both in blood glucose uptake and in
its release. Finally, GLUT2 is also expressed in pancreatic β-
cells, responsible for insulin synthesis, where it participates in
glucose sensing mechanism and, therefore, in the regulation
of glucose-stimulated insulin secretion [6].
On the other hand, GLUT3 transports glucose with
very high aﬃnity, although it is also able to transport
galactose, mannose, maltose, or xylose, but it is unable to
transport fructose [6, 10]. GLUT3 is primarily located in
tissues with high glucose demand and energy consumption,
possibly due to its high aﬃnity for glucose and its greater
transport capacity than other GLUT transporters [5], such
as GLUT1. Thus, while GLUT3 mRNA is ubiquitously
expressed in all human tissues, its protein is primarily located
in neurons [6]. GLUT3 transport capacity and its aﬃnity
for glucose are particularly important in this cell type, due
to the low concentration of glucose in the interneuronal
space compared to the concentration in serum. Therefore,
while in blood-brain barrier epithelium, GLUT1 (with a
lower aﬃnity for glucose than GLUT3) is expressed to
transport glucose from blood to interneuronal space, in
neurons, GLUT3 introduces this glucose. Indeed, although
GLUT1 is expressed in the remaining brain cells, the higher
transport capacity and aﬃnity of GLUT3 for glucose enables
preferential access to glucose in neurons. On the other hand,
GLUT3 has been detected in platelets and in the entire set
of white blood cells (lymphocytes, neutrophils, monocytes,
and macrophages). Interestingly, in these cells, GLUT3 is
located in an intracellular pool from which may be recruited
to the plasma membrane under energy needed conditions,
similar to GLUT4 translocation in response to insulin, in
muscle and adipose tissue. Thus, GLUT3 translocation is
promoted by diﬀerent physiological/signaling events, trig-
gered upon activation of these cells. In B-lymphocytes and
monocytes, insulin causes GLUT3 translocation. In platelets,
GLUT3 is translocated from intracellular formations, named
α-granules. This translocation is triggered by thrombin,
which induces a number of energy-dependent cell changes
producing cell aggregation and clot formation. GLUT3
translocation in neutrophils is triggered by exposure to
bacteria (or other specific activators). The activation of
neutrophils, monocytes, and lymphocytes involves also a
set of changes related to their function and associated to
energy expenditure: phagocytosis and elimination of bacte-
ria, immunoglobulin production, and antigen presentation
[10]. Finally, GLUT3 has been demonstrated to be essential
for survival and for pre- and postimplantation embryo
development [10, 11].
Another glucose transporter is GLUT4. GLUT4 can also
move glucosamine and dehydroascorbic acid. It displays
two sequences of internalization responsible for the protein
association with an intracellular compartment under basal
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insulin levels in plasma. When insulin binds to its recep-
tor, GLUT4 is rapidly translocated to plasma membrane,
increasing glucose uptake in the cell [6]. This translocation is
probably mediated by a putative phosphatidic acid-binding
motif, located in the cytoplasmic loop between helices 2
and 3 [12]. In addition, GLUT4 translocation can also be
triggered by exercise probably through the activation of
insulin-independent AMPK (AMP-activated protein kinase)
pathway [6]. In this way, GLUT4 expression is virtually
restricted to tissues with a marked insulin- and exercise-
dependent glucose transport; that is, heart, adipose tissue,
and skeletal muscle [13–15]. Because muscle and fat tissues
comprise a large fraction of the body mass, GLUT4 plays a
central role in glucose metabolism. Indeed, in rat adipocytes,
GLUT4 represents 90% of glucose transporters [15]. In
addition, according to its metabolic importance, GLUT4
expression is regulated in a development- and tissue-specific
manner [16]. Thus, GLUT4 expression is regulated during
muscle cell diﬀerentiation. In myoblasts, during alignment
step, GLUT4 expression is low and increases during cell
fusion [17]. In addition, the timing and magnitude of
GLUT4 expression are diﬀerent in every tissue, controlled by
diﬀerent factors, such as diet and exercise [18]. For example,
GLUT4 levels undergo a strong increase in plasmamembrane
of skeletal myocytes exposed to insulin [19–21]. Finally,
GLUT4, similar to GLUT1, displays an interesting connec-
tion with cancer, as both transporters are transcriptionally
repressed by p53 [9], a tumor suppressor protein important
in cell cycle control and apoptosis, processes that are altered
usually in cancer.
The last discovered member of class I sugar transporters
is GLUT14, which displays a remarkable similarity in gene
and protein sequence to GLUT3. Thus, its origin was
attributed to the GLUT3 duplication, occurred recently in
evolution (as it has not being found a GLUT14 ortholog in
mice). However, in contrast with the virtually ubiquitous
distribution of GLUT3, GLUT14 is expressed specifically in
testis [22].
2.5. Class II Facilitative Sugar Transporters. The class II fac-
ultative sugar transporters include GLUT5, GLUT7, GLUT9,
and GLUT11. GLUT5 in humans is only capable to transport
fructose, with no ability to transport glucose or galactose
[6]. GLUT5 expression is primarily located in small intestine
(upper jejunum), and in much lesser extent in kidney,
skeletal muscle, adipocytes, testes and sperm, and brain. The
role of GLUT5 is particularly important in small intestine,
where it is located in the apical membrane of enterocytes,
and it is responsible for the fructose transport from food. In
kidney, GLUT5 is expressed in the apical side of S3 proximal
tubule cells, where it is responsible for recapturing fructose
from glomerular filtrate [23].
GLUT7 can move both glucose and fructose with the
highest aﬃnity among GLUT transporters, whereas it is
unable to transport galactose, xylose, or 2-deoxyglucose.
GLUT7, like other fructose transporters (GLUT2, GLUT5,
and GLUT9), displays an isoleucine close to the end of
seventh transmembrane domain, which it is thought to
be important for substrate selectivity. Thus, other non-
fructose transporters (GLUT1, GLUT3, and GLUT4) display
a valine in that location. In GLUT7, the substitution of its
isoleucine in this region gives rise to the loss of fructose
transport capacity. GLUT7 mRNA is primarily expressed
in small intestine and colon, and in lesser extent in testis
and prostate. Importantly, the presence of GLUT7 both in
upper (jejunum) and lower (ileum) small intestine as well
as in colon allows hypothesizing a role for this transporter
in intestinal absorption of sugars. While SGLT1 and GLUT5
transport the bulk of glucose and fructose, respectively, in
jejunum and ileum, their concentration is expected to be
very low at the end of ileum and in colon. The expression of
GLUT7 in these areas, with its extraordinary aﬃnity for both
glucose and fructose, could help to capture the remaining
glucose and fructose which was not previously taken. As
with other sugar transporters, the expression of GLUT7 in
intestine is regulated in a substrate-dependent manner, and
it is increased when carbohydrate uptake is also increased
[24].
Regarding to GLUT9, there is no many data about its
transport activity, although it has been suggested that may
be a fructose transporter [6, 25]. However, most importantly,
GLUT9 is able to transport urate [25]. Thus, polymorphisms
and mutations in GLUT9 were correlated with elevated
serum uric acid levels and distinct diseases associated with
an imbalance in urate homeostasis [26–29]. These diseases
aﬀect primarily to organs and locations particularly sensitive
to urate imbalance, which match curiously with those loca-
tions where GLUT9 is primarily expressed, that is, articular
chondrocytes and kidney [25, 30, 31]. Other peculiar feature
of GLUT9 protein is the existence of two variants, which are
diﬀerentially expressed in polarized cells: while an isoform
is expressed in apical side, the second isoform is expressed in
basolateral side [25]. Finally, other important role for GLUT9
seems to be in relation to glucose sensing in pancreatic β-
cells, in collaboration with GLUT2 [32].
The last member to mention of the class II hexose
facilitative transporters is GLUT11, which seems to transport
glucose and fructose, but not galactose. GLUT11 displays
three splice variants, which, due to the presence of three
diﬀerent first exons, diﬀer in their N-terminal sequence of
aminoacids. Interestingly, these three GLUT11 isoforms are
expressed in a tissue-specific manner. Indeed, GLUT11a is
expressed in heart, skeletal muscle, and kidney; GLUT11b is
present in kidney, adipose tissue, and placenta; and GLUT11c
is located in heart, skeletal muscle, adipose tissue, and
pancreas [33].
2.6. Class III Facilitative Sugar Transporters. In general, little
is known about the members of class III facilitative sugar
transporters, but it includes GLUT6, GLUT8, GLUT10,
GLUT12, and HMIT. GLUT6 is a low-aﬃnity glucose
transporter, which is predominantly expressed in brain,
spleen, and peripheral leukocytes [4]. GLUT8 is able to
transport glucose with high aﬃnity, and its transport is
inhibited by fructose and galactose. Like GLUT6, GLUT8
contains a sorting motif in its amino-terminal end, which
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functions as signal to translocate the protein to membranous
systems, such as endosomes, lysosomes, or endoplasmic
reticulum [34]. GLUT8 is expressed primarily in testis and
brain [35]. GLUT10 is able to transport glucose, galactose,
and deoxyglucose. Its gene was mapped in chromosome
20, on the type 2 diabetes-linked region [36], although
diﬀerent association studies on distinct populations were
unable to correlate type-2 diabetes with any polymorphism
in GLUT10 gene [37–41]. However, mutations in GLUT10
gene were associated with arterial tortuosity syndrome, a
disease characterized by tortuosity, elongation, stenosis, and
aneurysm formation in arteries due to disruption of elastic
fibers in arterial wall. In addition, GLUT10 deficiency is
associated with the upregulation of TGF-β (tumor growth
factor-beta) pathway in arterial wall in Loeys-Dietz syn-
drome, a disease also characterized by arterial tortuosity and
aneurysms [42]. GLUT10mRNA was detected in heart, lung,
brain, liver, skeletal muscle, pancreas, placenta, and kidney
[36]. GLUT12 gene was identified in MCF-7 breast cancer
cells by homology with the insulin-stimulated GLUT4 gene,
although its protein sequence displays more similarity with
GLUT10. However, its similarity with GLUT4 is particularly
significant, because, like GLUT4, GLUT12 is intracellularly
located in absence of insulin [43]. GLUT12 is expressed
in adipose tissue, small intestine, skeletal muscle [43], and
placenta [44]. Curiously, in type I oxidative fibers of skeletal
muscle, GLUT4 and GLUT12 are predominantly expressed
regarding to the remaining GLUT transporters [45]. Indeed,
similar to GLUT4, insulin is able to induce the transloca-
tion of GLUT12 from an intracellular location to plasma
membrane in skeletal muscle [46]. Finally, HMIT [H(+)-
myoinositol transporter; solute carrier family-2 (facilitated
glucose transporter), member 13; gene name: SLC2A13]
is a specific transporter for myoinositol, and its activity
is stimulated by the decrease of the extracellular pH [47].
HMIT is predominantly expressed in brain, where it is
able to transport IP3 (inositol trisphosphate) and may con-
tribute to diﬀerent signaling processes related with neuronal
function [48].
3. Expression of Sugar Transporters in Cancer
Many tumors display high rates of glucose uptake. It has been
proposed diﬀerent hypothesis to explain this exacerbated
glucose consumption, including the increase of hexokinase
expression [49, 50], the decrease of glucose-6-phosphatase-
mediated glucose dephosphorylation [51], and/or the over-
expression of sugar transporters [52]. Agreed with this last
explanation, GLUT1 overexpression has been observed in
many human cancers. In addition, GLUT1 expression levels
were inversely correlated with prognosis, as the deregulation
of GLUT1 expression may reflect the presence of alterations
in diﬀerent signaling pathways. In fact, elevated levels of
glucose uptake, one of the hallmarks of malignant cells, are
induced by activated ras or src oncogenes which are key
elements in the transduction of multiple signaling pathways
[3]. In this regard, it has been recently published that, in
colorectal cancer cell lines, mutations in KRAS (v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog) or BRAF (v-
raf murine sarcoma viral oncogene homolog B1) genes, are
able to trigger an overexpression of GLUT1 and an increase of
the glucose uptake. Furthermore, the exposition of wild type
colorectal cancer cell lines to low levels of glucose contributes
to the development of mutations in KRAS, which give rise,
instead, to the upregulation of GLUT1 and to an increase in
glucose uptake [53]. Other important alterations in cancer
involved in GLUT1 overexpression aﬀect to MYC oncogene
expression and to the local hypoxia pathway [54, 55].
Moreover, tumor cells may also express glucose transporters
that are not substantially expressed under normal conditions.
Below, we will summarize the available information about
the expression of sugar transporters in diﬀerent types of
cancer (Table 2).
Similar to GLUT1, SGLT1 induction is also used by can-
cer cells to enhance their glucose uptake and their glycolysis,
so that cancer cells obtain suﬃcient energy for maintaining
their expansive growth [56]. However, there are few studies
about the expression of SGLT transporters in tumors. In
a pioneer study, it was demonstrated that the expression
or activity of an undefined SGLT cotransporter in HT29
colon cancer cell line is modulated by addition/deprivation
of glucose in culture [57]. In a most recent study, the
expression of SGLT1 and SGLT2 genes was analyzed by
RT-PCR in autopsies from normal lung and lung primary
tumors together with their metastatic lesions. The SGLT1
and SGLT2 expression was found unchanged between lung
tumor samples and paired normal lung tissue. By analyzing
the metastatic lesions (from liver and lymph nodes) of
lung tumors, it was found that the expression of SGLT2
was significantly higher in metastasis areas than in primary
tumors, whereas SGLT1 expression did not display changes
[58]. This study is an interesting approach to the study
of SGLT1 and SGLT2 expression in lung cancer although
the nature of the samples (autopsies) may minimize the
significance of the obtained results. Moreover, by using an
immunohistochemical approach, the expression of SGLT1
(together with BCL2 and p53) was analyzed in pancreatic
cancer to relate the data obtained with diﬀerent survival
parameters. In this study, SGLT1 overexpression was sig-
nificantly correlated with disease-free survival in pancreatic
adenocarcinomas [59]. In addition, high SGLT1 expression
in pancreatic primary tumors was correlated with high Bcl-2
expression. This prospective study suggests SGLT1 and Bcl-
2 as potential prognostic biomarkers for pancreatic cancer,
although it should be validated by a more sensitive technique
as qRT-PCR.
In other study, it has been revealed a surprising link
between glucose uptake performed by SGLT1, survival of
cancer cells, and EGFR (epidermal growth factor receptor),
whose malfunction is involved in many carcinogenetic
processes. In this study, authors uncover a new EGFR role
in human cancer cells, whereby it is able to maintain glucose
uptake by cells through the SGLT1 stabilization, promoted by
the EGFR-SGLT1 interaction. Therefore, the EGFR-SGLT1
association-dependent maintenance of intracellular glucose
level avoids autophagic cell death, promoting survival of
cancer cells [60].
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Table 2: Sugar transporters and their expression in cancer.
Transporter Tissues Roles and properties
SGLT transporters
SGLT1 Small intestine, kidney.
Intestinal absorption of glucose from meal. Renal
reabsorption of glucose.
SGLT2 Kidney. Renal absorption of glucose from glomerular filtrate.
Class I GLUT transporters
GLUT1 Erythrocytes, brain (blood-brain
barrier).
Basal glucose uptake.
GLUT2 Liver, pancreatic islet cells, small
intestine, kidney.
Glucose sensing in pancreatic β-cells. Trans-epithelial
glucose and fructose transport. High-capacity,
low-aﬃnity glucose transporter.
GLUT3 Brain (neuronal), testis. Glucose neural transporter.
GLUT4 Muscle, heart, adipose tissue.
Expressed in tissues with insulin-stimulated acute
glucose transport. In response to insulin, it is
translocated to plasma membrane.
GLUT14 Testis.
Class II GLUT transporters
GLUT5 Small intestine, testis, muscle. Only fructose transporter.
GLUT7 Intestine, testis, prostate.
GLUT9 Liver, kidney.
GLUT11 Heart, adipose tissue, kidney,
placenta, muscle.
GLUT11 has three isoforms: GLUT11a, GLUT11b, and
GLUT11c, with distinct tissue distribution.
Class III GLUT transporters
GLUT6 Brain, spleen, leukocytes.
GLUT8 Brain, testis, adipocytes.
GLUT10
Heart, lung, brain, liver, skeletal
muscle, pancreas, placenta, and
kidney.
Mutations in GLUT10 were associated with arterial
tortuosity syndrome. GLUT10 deficiency is associated
with the upregulation of TGFB pathway in Loeys-Dietz
syndrome.
GLUT12 Placenta, adipose tissue, small
intestine and skeletal muscle.
In skeletal muscle, it is translocated to plasma
membrane in response to insulin, like GLUT4.
HMIT Brain. Myoinositol transporter.
Deregulated GLUT expression has been described in
many tumor types [61]. In RCC (renal cell carcinoma), the
expression of diﬀerent GLUTs is altered in a histological
subtype-specific manner. Thus, in conventional clear cell
RCC, GLUT1 expression is increased, while the expression of
GLUT4, GLTUT9, and GLUT12 decreases versus the healthy
kidney. In papillary RCC, GLUT12 is expressed at lower
levels than normal kidney. In chromophobe RCC, GLUT4
expression is increased, while the expression of GLUT2
and GLUT5 decreases. Finally, no changes were observed
in oncocytoma RCC subtype in terms of expression of
GLUT transporters compared to normal kidney [62]. On the
other hand, it was analyzed the GLUT1 expression related
to histological subtype and diﬀerent clinical parameters in
RCC. GLUT1 shows higher expression in clear cell RCC
versus normal kidney [63], cromophobe RCC [64], and
papillary RCC [63, 64]. Despite the GLUT1 expression
in clear cell RCC, this data could not be associated with
clinicopathological parameters [63, 64], but its expression in
this RCC subtype was correlated with the HIF1A (hypoxia-
inducible factor 1-alpha) expression [64].
Regarding to prostate tumors, there are few studies of
GLUT expression in relation to healthy tissue or to clinical-
pathological parameters. It has been studied the role and
expression of GLUT1 and GLUT12 in prostate cancer cell
lines and tumor and hyperplastic prostate tissue sections
through diﬀerent technical approaches. The mRNA and
protein of GLUT1 and GLUT12 were detected in all four
prostate carcinoma cell lines assayed. Regarding to the
analysis in tissue sections, the expression of GLUT1, but
not GLUT12 expression, was detected in benign prostatic
hyperplasia. Conversely, in prostatic tumor tissue GLUT12
expression was detected but not GLUT1 expression. It is
unknown the relevance and the explanation of this change
in the pattern of GLUT1 and GLUT12 expression during
prostate tumor progression [65].
In lung cancer, there are also few studies on the alteration
in the expression of GLUT transporters during tumor
development and their potential role as putative clinical-
pathological biomarkers. In the most recent study, it was
studied and compared the expression of GLUT transporters
between primary tumors with diﬀerent histology, liver
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metastasis, and normal lung and liver tissues, obtained
from 105 autopsy samples. The expression of GLUT1
was significantly higher in primary lung tumors than in
normal lung. In liver metastasis, the GLUT3 and GLUT5
expression was significantly higher than in normal lung
tissue and primary lung tumors, while the GLUT1 expression
did not show diﬀerences while comparing normal lung
to primary lung tumors. In addition, GLUT5 expression
was significantly higher in metastatic liver lesions than
in normal liver, and the expression for GLUT3 showed
the same tendency, without reaching signification. GLUT1
expression did not displayed diﬀerences between normal
and metastatic liver tissue. In conclusion, the expression
profile of GLUTs analyzed is diﬀerent in primary lung tumors
and liver metastasis, suggesting an increase in the use of
GLUT transporters (through the overexpression of GLUT3
and GLUT5) and, probably an increase in glucose/fructose
uptake in metastatic areas [66]. Despite the robust technical
approach (RT-PCR) used, the conclusions of this study must
be taken with caution as the results obtained with autopsies
may diﬀer from the results obtained using biopsies, a type
of samples generally utilized for cancer diagnosis. Therefore,
from this study, it is diﬃcult to associate the expression of
GLUTs analyzed with any clinical-pathological parameter.
However, in a previous study, it was analyzed the biological
significance of GLUT1 and GLUT3 overexpression on 289
archival biopsies from stage I nonsmall cell lung cancer
(NSCLC) patients. During this retrospective study, GLUT1
and GLUT3 overexpression was detected primarily in poorly
diﬀerentiated and undiﬀerentiated tumors. In addition, the
overexpression of GLUT1 and/or GLUT3 was associated
with poor survival in all NSCLC patients, but especially in
patients with well andmoderately diﬀerentiated tumors [67].
Therefore, GLUT1 and GLUT3 overexpression may be used
as prognostic indicators in stage I nonsmall cell lung cancer
patients.
Regarding to GLUT expression in breast cancer, in a
preliminary study by immunostaining, GLUT12 expression
was detected in invasive and noninvasive breast carcinomas,
while it was absent (or with weak staining) in adjacent
normal breast tissue [68]. In other studies, GLUT5 expres-
sion was also detected both in breast cancer cell lines
and breast cancer tissues, while in normal breast tissues
GLUT5 expression was absent [69, 70]. In addition, GLUT1
expression was also found in breast tumors and it was
possible its association with the invasive ability despite the
absence of a clear correlation with prognosis [71, 72].
In gastric cancer, GLUT1 expression was assayed in
an immunohistochemical study performed on 617 gas-
tric carcinomas and 50 tubular adenomas of stomach.
GLUT1 expression was primarily restricted to papillary,
tubular, and diﬀerentiated adenocarcinoma (low positivity in
signet ring cell carcinoma and mucinous adenocarcinoma).
GLUT1 expression appears in advanced stages of gastric
tumor development and increases with disease progression.
Moreover, GLUT1 expression was associated with depth
of invasion, lymphatic and venous invasion, lymph node
and hepatic metastasis, and carcinoma stage. In addition,
the survival of patients with tumors that expressed GLUT1
was significantly shorter than those patients with GLUT1-
negative tumors [73]. In a recent study, GLUT1 expression
was also detected in pancreas carcinoma, although it was
not found significant correlation with any prognostic factor
[74]. However, GLUT1 forced overexpression in pancreatic
cancer cell lines enhances their invasive capacity through the
induction of MMP2 (matrix metalloprotease 2) expression
and activity [75]. In addition, it has been demonstrated
that GLUT1 expression is responsible for the continuous
insulin release in insulinoma patients under hypoglicemia
[76, 77]. GLUT1 expression was also retrospectively studied
in a cohort of 112 colon carcinoma biopsies. As result of
this study, GLUT1 expression was associated with tumor
progression and poorer prognosis in colorectal cancer [78].
By immunohistochemistry, the expression of GLUT1 was
analyzed in the site of deepest invasion of 152 colorectal
cancer samples. The aim of this study was assessing the
value of GLUT1 as surrogate biomarker for prognosis and
metastatic potential in colorectal cancer. The expression
of GLUT1 and Ki-67, as cell proliferation marker, were
analyzed in three diﬀerent zones of tumor samples: the
deepest invasive site, the central portion, and the superficial
part. In central and superficial part of tumors, no significant
diﬀerences were detected between GLUT1 expression, Ki-67
expression, and clinicopathological parameters. However, in
the deepest invasive site, GLUT1 expression was associated
with Ki-67 labeling index. In addition, in patients who
underwent curative surgery, the GLUT1 expression at the
deepest invasive site was significantly associated with poorer
prognosis. Therefore, GLUT1 expression at deepest site of
tumor invasion may be used as predictor of poor prognosis
in advanced colorectal cancer [79]. Probably, the expression
of GLUT1 in deepest zones of colorectal tumors may be
related to the degree of hypoxia reached in these zones, since
GLUT1 is a HIF1 target [80], which is activated in hypoxic
environments. Indeed, in other retrospective study on 49
biopsies from rectal carcinoma patients, the expression of
GLUT1 was analyzed in relation to diﬀerent clinical outcome
parameters to asses its potential use as biomarker to detect
tumor hypoxia. This semiquantitative study was performed
using immunohistochemistry. As result, the GLUT1 over-
expression was significantly associated with poorer overall
survival (probably due to a poorer metastasis-free survival),
although it was not detected significant changes in overall
survival between patients suﬀering GLUT1 positive tumors
and patients with GLUT1 negative tumors. In addition,
although there was a clear correlation between GLUT1
expression and tumor depth, it was only found a significant
association between survival and GLUT1 expression in the
deep tumor part. This may be indicative of the relationship
existing among poor prognosis, hypoxia, and GLUT1 expres-
sion, since a most intense degree of hypoxia is reached in
deepest parts of tumors. However, the regulation of GLUT1
by other stimuli hinders the potential clinical use of GLUT1
as a surrogate biomarker for tumor hypoxia [81].
Regarding to brain tumors, the expression of GLUT1
and GLUT3 was analyzed in a series of 20 diﬀerent
brain tumors [82]. Although the authors failed to detect
GLUT1 immunoreactivity in all brain tumors analyzed
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(astrocytomas, meningiomas, and gliomas), they could
detect GLUT3 immunoreactivity in high grade gliomas. In
addition, they demonstrated the induction of GLUT1 and
GLUT3 mRNAs. While in astrocytomas, GLUT1 mRNA
increased with grade, in meningiomas, GLUT1 mRNA
showed no changes. In gliomas, GLUT3 mRNA also showed
a significant increase correlated with grade, in line with the
increase observed also in protein immunoreactivity [82].
Moreover, GLUT3 expression may also be related to malig-
nant transformation in astrocytomas as well as to aberrant
neovascularisation in glioblastomas [83]. In fact, GLUT3
was also found upregulated in glioblastomamultiforme [84].
Finally, GLUT5 was also found to be expressed in microglia
from human gliomas [85].
In head and neck carcinoma, GLUT1 and GLUT3
expression was detected [86, 87], while the GLUT2 and
GLUT4 expression was not [87]. The expression of GLUT1
and GLUT3 was analyzed on 38 head and neck carcinomas
to determine the biological significance of GLUT overex-
pression in this type of tumors. GLUT1 and GLUT3 gene
expression was significantly higher in head and neck tumors
than in nontumor adjacent areas and normal tissue. The
expression level of GLUT1 gene and protein was correlated
with poor survival, clinical stage, and lymph nodemetastasis,
while GLUT3 gene expression was correlated only with
lymph node metastasis. However, GLUT3 protein was not
detected in any of the analyzed cases from head and neck
carcinoma [86]. According to this evidence, in a previ-
ous immunohistochemical study, the expression of GLUT3
protein was not detected in normal mucosa, preneoplastic
and neoplastic lesions from head and neck squamous cell
carcinoma, while high level of GLUT1 expression was
correlated with higher grade of dysplasia. The increased
expression of GLUT1 in dysplastic lesions and its sustained
expression in tumor samples indicate that alterations in
GLUT1 expression occur at early stages during development
of head and neck squamous carcinomas [88]. Thus, GLUT1
may be an interesting biomarker to detect preneoplastic
lesions and to perform a clinical intervention before the
development of head and neck carcinoma. Moreover, it
was also performed an analysis on 118 oral squamous cell
carcinoma patients to determine the relationship between
GLUT1 expression and glucose uptake with overall survival.
The analysis showed that it was significant association
between GLUT1 overexpression, increased glucose uptake,
and poor survival in oral squamous cell carcinoma patients
[89]. These data support that GLUT1 could be a good
biomarker for prognosis in these patients.
The expression of GLUT1 was also extensively studied
in sarcomas. In these tumors, the glucose uptake, measured
through FDG (18F-Deoxyglucose) signal, correlates with
the presence and intensity of GLUT1 expression [90]. The
prognostic significance of GLUT1 expression was analyzed
by immunohitochemistry in 67 patients with bone and soft-
tissue sarcomas, and it was found that GLUT1 overexpression
was significantly correlated with poor overall survival and
with higher histological grade [91]. Therefore, GLUT1
overexpression could be used as a surrogate prognostic
biomarker in patients with bone and soft-tissue sarcomas.
In endometrial cancer, the expression of GLUT1 and
GLUT8 was analyzed in normal, atrophic, and malignant
tissue. In normal endometrium and endometrial tumors,
GLUT1 and GLUT8 were found to be expressed at dis-
tinct intracellular locations depending on the presence or
absence of malignancy. In addition, GLUT1 upregulation
was significantly associated with an increase of histological
grade in endometrial tumors. Regarding to GLUT8, it was
found an increase of expression in all endometrial tumor
subtypes versus atrophic endometrium [92]. Therefore, since
the expression of GLUT1 and GLUT8 increases during tumor
progression and development of endometrial tumors, these
GLUTs could be used as potential biomarkers for prognosis
and clinical follow-up of endometrial cancer patients.
Finally, the expression of GLUT1, GLUT2, GLUT3,
GLUT4, and GLUT10 was assayed by quantitative RT-PCR
in 152 normal and pathological thyroid samples. Only
GLUT1 showed a significant increase of expression in thyroid
carcinoma versus normal tissue [93].
4. Glut Transporters and Anticancer Therapy
4.1. Pharmacological Modulation of Glucose Uptake by
Current Anticancer Drugs. Nowadays, anticancer therapy
is based on two main approaches. Firstly, the tradi-
tional approach is based on conventional chemotherapy
addressed unspecifically against general cell processes, such
as nucleotide biosynthesis. Secondly, novel approaches are
based on the use of targeted therapy, which includes drugs
designed to block specific components of signaling pathways
deregulated in cancer. In this way, drugs as the multitar-
geted TKIs (tyrosine kinase inhibitors) sunitinib (Sutent,
Pfizer) and sorafenib (Nexavar, Bayer), or temsirolimus
(Torisel, Pfizer), an analog of rapamycin, inhibitor of the
mTORC1 (mammalian target of rapamycin complex 1)
formation, have contributed to substantial improvements
in the treatment of patients aﬀected of diﬀerent tumors,
such as for example RCC. However, probably due to the
recent implantation of these targeted therapies, their eﬀect
on GLUT transporters remains, in many aspects, elusive. In a
recent work [94], it was demonstrated that, in renal angiomy-
olipomas, which lack TSC1/TSC2 (tuberous sclerosis) com-
plex and display a constitutive activation of mTORC1,
the glucose uptake was surprisingly low. It is surprisingly
because mTORC1 pathway was involved in the upregulation
of glycolitic enzymes and GLUT transporters [95], as this
upregulation is reached through the activation of HIF1A and
VEGF signaling. The explanation for the low glucose uptake,
under the absence of TSC1/2 complex and the mTORC1
constitutive activation, is that the traﬃcking to membrane
of GLUT1, GLUT2, and GLUT4 proteins is impaired. This is
important because the deregulation and activation of mTOR
[mammalian target of rapamycin; oﬃcial name: mechanistic
target of rapamycin (serine/threonine kinase)] pathway may
be behind of many tumor types. But, as it has been above
described, tumors display an enhanced glucose uptake and
GLUT transporter expression. Therefore, mTORC1 altered
activity is insuﬃcient to explain the increase of glucose
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uptake in tumors, and it is possible to hypothesize the
existence of additional molecular events, beyond mTOR
signaling, which contribute to enhance glucose consumption
and metabolic hyperactivity during tumorigenesis. However,
mTOR inhibitors (e.g., temsirolimus) are able to reduce
glucose uptake in tumors [96] (e.g., kidney cancer), although
this eﬀect is probably related to the inhibition on tumor
angiogenesis (inhibiting the mTOR-dependent HIF1/VEGF
signaling) and glucose deprivation of tumor, rather than
with a possible direct eﬀect of mTOR pathway on GLUT
expression and/or traﬃcking. In other recent study on an
animal model, it was analyzed the utility of mTOR inhibitors
(rapamycin) as therapeutic strategy to treat insulin-resistant
states, including type 2 diabetes. This supposition is based
on the fact that mTOR and its downstream S6K1 (ribosomal
protein S6 kinase, 70 kDa, polypeptide 1) are able to
downregulate IRS (insulin receptor substrate) proteins, with
the consequent reduction of insulin-dependent signaling
through PI3K/Akt (phosphoinositide 3-kinase/v-akt murine
thymoma viral oncogene) pathway, GLUT4 translocation to
plasma membrane, and glucose uptake. However, in this
study, rapamycin appears to exacerbate diabetes, increasing
the resistance to insulin, and reducing β-cell function in
pancreas where it triggers apoptosis [97].
Regarding to TKIs (e.g., sunitinib), although still little is
known about their eﬀect on GLUT transporters in tumors,
the antiangiogenic eﬀect triggered by these drugs may be
also involved in the reduction of glucose uptake, through
the deprivation of tumor accessibility to glucose. However,
it is feasible the existence of some direct eﬀect of TKIs on
GLUT expression and/or traﬃcking as there were detected
side eﬀects of these drugs, such as asthenia. In this way, some
TKIs, as sunitinib, which is a multikinase inhibitor with a low
specificity by its targets, may block multiple RTKs [such as
INSR (insulin receptor) or IGFR1 (insulin-like growth factor
1 receptor)] or intermediate kinases (such as AMPK, PI3K,
or Akt) in distinct signaling pathways, with direct action
on glucose uptake or GLUT expression. Currently, there are
several small molecules and antibodies under investigation
designed against IGFR in diﬀerent clinical trials. These new
drugs probably may play some role on the expression and
function of sugar transporters, since IGFR pathway is one of
key pathways which controls sugar uptake in normal cells.
So far, selective GLUT inhibitors are not available in
the clinical setting. Several selective GLUT inhibitors, such
as fasentin or apigenin, have been tested in vivo and in
vitro. These selective agents acts by blocking the glucose
uptake from tumor cells and they have been shown to
sensitize cells to death and avoid the normal activation of the
PI3K/Akt/mTOR intracellular pathway [98, 99]. However,
the bioavailability of these agents prevents the transition to
clinical practice.
4.2. Glucose Uptake Inhibition-Based Anticancer Therapies.
As we have just reviewed, most tumors exhibit increased
expression of sugar transporters as well as enhanced glycol-
ysis. This phenomenon, which takes place even in aerobic
conditions, that is, in presence of suﬃcient oxygen to carry
out mitochondrial respiration, is known as Warburg eﬀect
[1], and is considered as a fundamental metabolic alteration
duringmalignant transformation. There are several hypothe-
ses to explain this phenomenon, such as mitochondrial mal-
function, generation of a hypoxic tumor microenvironment,
defects in oncogenic signaling, or metabolic abnormalities.
In any case, the increased dependence of tumor cells on
sugars and glycolytic pathway to generate ATP provides the
biochemical basis to design drugs that preferentially kill
cancer cells through the pharmacological inhibition of sugar
transport and/or glycolysis.
The glycolytic inhibitors are particularly eﬀective against
tumors that display an increased glycolytic activity associated
with mitochondrial defects or hypoxic conditions. These
events are normally related to resistance and low response
to conventional chemotherapy. Increased glycolysis is present
in a wide spectrum of human tumors, and therefore the
development of novel glycolytic inhibitors as anticancer
agents would have broad therapeutic applications [100]. In
this way, it has been recently presented a phase I trial to
study the pharmacokinetic of 2-Deoxyglucose, a glycolytic
inhibitor analog for glucose, to treat advanced solid tumors
and hormone refractory prostate cancer [101]. This agent
leads to sensitization of tumor cells to other pharmacological
stimuli [102].
The inhibition of sugar transport may be reached
through diﬀerent approaches. One of these approaches is the
use of antisense oligonucleotides against GLUT genes. This
has been proved with GLUT5 which is expressed in breast
cancer, but not in normal breast tissue [69, 70]. Two breast
cancer cell lines, MCF-7, which is estrogen-receptor positive
and mimics an early stage of breast cancer, and MDA-
MB-231, which is estrogen-receptor negative and mimics a
late stage in breast cancer progression, were exposed to a
15-nucleotide sequence around the start codon of GLUT5,
used as an antisense oligonucleotide to specifically block
GLUT5 expression. It was found that the oligonucleotide
anti-GLUT5 triggered antiproliferative eﬀects on both breast
cancer cell lines. This action, unlike current drugs used
against breast cancer (e.g., tamoxifen), seemed to be specifi-
cally addressed on breast tumor cells (which express GLUT5)
with independence of estrogen-receptor status [103]. An
additional approach consists of the inhibition of cell sugar
uptake. In this way, it has been demonstrated that D-allose, a
rare sugar, is able to interfere with the D-glucose uptake and
to induce apoptosis in head and neck tumor cells, inhibiting
their growth [104].
5. Discussion
Sugars are the main substrate utilized by cells for energy
production, so it is easily understandable their importance
for life, both in normal cell physiology and in disease
conditions. A key point to take into account in the study
of sugar’s metabolism is their introduction inside of cells.
Sugars are moved through plasma membrane using carrier
proteins, which are grouped in two main types: facilitative
transporters, named GLUTs, and sodium-dependent trans-
porters, named SGLTs. The fundamental diﬀerence between
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these two types of transporters is their dependence on
energy usage to perform the transport: while the transport
by GLUTs is performed through an energy-independent
mechanism, the transport by SGLTs is energy-consuming.
However, the basic structure of sugar transporters is similar.
It is constituted by a number of transmembrane helix
grouped to form a channel by which sugar crosses. Indeed,
the similarity within each group goes beyond of structure,
with important sequence identity between distinct members.
The major diﬀerence between sugar transporters in each
group is their main site of expression, since they show
strong tissue specificity. For example, GLUT1 is often known
as “erythroid” GLUT, as its expression is preponderant in
erythrocytes. In fact, each GLUT carrier displays a number
of particular features which are the suitable and essentials
for energy requirements and proper function of the specific
tissue where the GLUT is expressed. For example, GLUT4
is primarily expressed in insulin-sensitive tissues, where is
able to translocate from an intracellular pool to plasma
membrane [12–15]. Each tissue displays changes in energy
requirements due to their particular physiology (e.g., skeletal
muscle), so the glucose uptake must be adapted for these
tissue specific requirements through internal or external
stimuli directly related to tissue function, such as insulin or
exercise. So, when a muscle is subjected to intense activity
due to exercise, its glucose uptake must increase in order
to assure the necessary energy supply and respond to the
increase in glucose expenditure. This objective is achieved
through a complex network of exercise-dependent signals
which culminate with the mobilization of intracellular
pool of GLUT4 to plasma membrane. Therefore, it is not
surprising that alterations in the expression of GLUTs or
their malfunction can trigger diﬀerent diseases, such as
diabetes. In tumors, alterations in GLUTs contribute to
their maintenance and their virulence. These alterations in
GLUTs lies in other background alterations which are behind
diﬀerent carcinogenetic events and aﬀect simultaneously
to multiple processes, as sugar uptake. For example, p53,
a tumor suppressor protein with important functions in
promoting apoptosis and cell cycle arrest when cell suﬀers
any aggression or damage, is mutated or transcriptionally
deregulated in many types of cancer. This is an event which
is thought to drive many aspects of carcinogenesis. GLUT
deregulation probably is among these aspects, as p53 is
able to transcriptionally repress GLUT1 and GLUT4 gene
expression [9]. Other signaling systems that directly aﬀect
to GLUT expression may be also altered in cancer, such as
the PI3K/Akt/mTOR pathway which conveys the signal from
insulin to cell. Moreover, carcinogenetic events which aﬀect
to EGFR may be behind the increased glucose uptake and
survival of cancer cells through the stabilization of SGLT1
carrier, as it has been recently demonstrated [59]. Indeed,
it was shown that KRAS activating mutations, occurring in
diﬀerent types of tumors, can be behind GLUT1 overexpres-
sion and also can be responsible for the increased glucose
uptake in colorectal cancer cell lines [53]. All these alterations
drive to an unfailing increase in sugar uptake which is
one of hallmarks of cancer, such as it has been highlighted
many years ago with the discovery of Warburg eﬀect [1].
The increase in sugar uptake feeds to cancer cells in their
expansive activity in which they burn huge energy amounts.
This energy can be obtained throughmultiple ways, although
the main system used by cancer cells is the glycolysis as
these cancer cells normally display a number of physiological,
metabolic, and genetic abnormalities that make impossible
the mitochondrial oxidative phosphorylation. Glycolysis is
an ineﬃcient way to obtain energy which explains the vast
necessity of sugar by cancer cells. In this way, there is
some evidence showing the relationship between glucose
transporter levels and prognosis in cancer. Therefore, it is
easy to imagine distinct pharmacological approaches for the
design of drugs to attack the feeding source of cancer cells. A
first approach could be the blockade of signaling components
altered in cancer that enhance the expression of sugar
transporters, following with the current pharmacological
design of multikinase inhibitors. Other strategies are the
administration of glycolytic inhibitors, the direct blockade
of sugar transporters, and the administration of nonmetab-
olizable sugar analogs. The use of glycolytic inhibitors has
the disadvantage of their limited specificity, as they target
any cell of organism. However, the use of nonmetabolizable
sugar anologs is most plausible because cancer cells take
up primarily glucose, whereas the remaining cells of the
organism are able to eﬃciently metabolize a number of
other sugars. Finally, the use of sugar carrier inhibitors is
perhaps the most interesting option, as it is possible to
designmolecules that specifically inhibit each carrier protein.
This could be used in the tumors where a sugar carrier
is specifically expressed or where a particular sugar carrier
shows an aberrant overexpression. The advantage of this
approach is the relative overlapping of functions among
sugar transporters (i.e., one carrier protein can transport
distinct sugars with more or less aﬃnity and, thus, to
supply the lack of other), although their strong tissue-specific
distribution is an issue to take into account. In any case, none
of these pharmacological approaches are being currently
explored. Current targeted therapies are not designed to
decrease the sugar uptake by cancer cells, although this
eﬀect may be achieved as a secondary result. For example,
sunitinib, a TKI used in the treatment of RCC and GIST
(gastrointestinal stromal tumors), reached excellent results
due to its antiangiogenic eﬀect. The additional decrease in
glucose uptake observed in cancer cells is probably due to the
loss of tumor vasculature, with the consequent reduction in
sugar supply. However, as asthenia is the most important side
eﬀect triggered by these TKIs, it is also possible some type of
pharmacological modulation on the expression or function
of sugar transporters. Undoubtedly, it is still necessary to
carry out an important eﬀort in understanding the role
of sugar transporters and their deregulation in cancer, as
well as to tackle the design of eﬃcient drugs specifically
targeted against the glucose uptake by cancer cells. In
addition, prospectively designed trials measuring glucose
transporter levels are needed to evaluate the potential role
that these transporters may have in advanced cancer and
their modulation by anticancer drugs. We think that GLUTs
emerge as one of the key drivers on tumor cell growth and
may represent a target for the development of new drugs.
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